GENERAL INFORMATION 
It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted. 

Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care  criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.

Policy
INDICATIONS FOR HEART CT
Congenital Heart Disease^(1,2)
For all indications below, either CT or CMR can be performed: 

• All congenital lesions: prior to planned repair and for change in clinical status and/or new concerning signs or symptoms

Patent Ductus Arteriosus 

• Routine surveillance (1-2 years) in a patient with postprocedural aortic obstruction (AUC 7)

Aortic Dilation 

• Routine surveillance (6-12 months) in a child with aortic sinus and/or ascending aortic dilation with increasing size (AUC 7)

Aortic Coarctation and Interrupted Aortic Arch

• Routine surveillance (3–5 years) in a child or adult with mild aortic coarctation (AUC 7)
• Post procedure (surgical or catheter-based) routine surveillance (3–5 years) in an asymptomatic patient to evaluate for aortic arch aneurysms, in-stent stenosis, stent fracture, or endoleak (AUC 8)

Tetralogy of Fallot

• Post procedure routine surveillance (2–3 years) in a patient with valvular or ventricular dysfunction, right ventricular outflow tract obstruction, branch pulmonary artery stenosis, arrhythmias, or presence of an RV-to-PA conduit (AUC 7)

D-Loop Transposition of the Great Arteries

• Post procedure routine surveillance (3–5 years) in an asymptomatic patient (AUC 7)
• Post procedure routine surveillance (1–2 years) in a patient with dilated aortic root with increasing size, or aortic regurgitation (AUC 7)
• Post procedure routine surveillance (3–12 months) in a patient with ≥ moderate systemic AV valve regurgitation, systemic RV dysfunction, LVOT obstruction, or arrhythmias (AUC 7)

Congenitally Corrected Transposition of the Great Arteries

• Unrepaired: routine surveillance (3–5 years) in an asymptomatic patient (AUC 7)
• Postoperative: routine surveillance (3–5 years) in an asymptomatic patient (AUC 7)
• Postoperative anatomic repair: routine surveillance (6–12 months) in a patient with valvular or ventricular dysfunction, right or left ventricular outflow tract obstruction, or presence of an RV-to-PA conduit (AUC 7)
• Postoperative physiological repair with VSD closure and/or LV-to-PA conduit: routine surveillance (3–12 months) in a patient with ≥ moderate systemic AV valve regurgitation, systemic RV dysfunction, and/or LV-to-PA conduit dysfunction (AUC 7)

Truncus Arteriosus

• Routine surveillance (1–2 years) in an asymptomatic child or adult with ≥ moderate truncal stenosis and/or regurgitation (AUC 7)
• Single-Ventricle Heart Disease (includes hypoplastic left heart syndrome, double-inlet LV, double-inlet RV, mitral atresia, tricuspid atresia, unbalanced A-V septal defect): postoperative routine surveillance (3-5 years) in an asymptomatic patient (AUC 7)

Cardiomyopathy (3)

• Quantification of myocardial (muscle) mass (CMR or CT) (4,5,6)
• Assessment of left ventricular systolic dysfunction when prior noninvasive imaging has been inadequate (AUC 7)
• Assessment of right ventricular morphology in suspected arrhythmogenic right ventricular cardiomyopathy (AUC 7) (7), based upon other findings such as (4):
  • Nonsustained VT
  • Unexplained syncope
  • ECG abnormalities (6)
  • First-degree relative with positive genotype of ARVC (either, but CMR is superior to CT) (4,6)

Valvular Heart Disease (8,9)

• Characterization of native or prosthetic valves with clinical signs or symptoms suggesting valve dysfunction, when TTE, TEE, and/or fluoroscopy have been inadequate (AUC 7)
• Evaluation of RV systolic function in severe TR, including systolic and diastolic volumes, when TTE images are inadequate and CMR is not readily available
• Pulmonary hypertension in the absence of severe valvular disease (10)
• Evaluation of suspected infective endocarditis with moderate to high pretest probability (i.e., staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device), when TTE and TEE have been inadequate
• Evaluation of suspected paravalvular infections when the anatomy cannot be clearly delineated by TTE and TEE

Evaluation of Intra- and Extra-cardiac Structures (3)

• Evaluation of cardiac mass, suspected tumor or thrombus, or cardiac source of emboli, when imaging with TTE and TEE have been inadequate (AUC 7)
• Re-evaluation of prior findings for interval change (i.e., reduction or resolution of atrial thrombus after anticoagulation (AUC 8), when a change in therapy is anticipated (AUC 7) (3,11)
• Evaluation of pericardial anatomy (AUC 8), when TTE and/or TEE are inadequate or for better tissue characterization of a mass and detection of metastasis [CMR superior for physiologic assessment (constrictive versus restrictive) and tissue characterization, CT superior for calcium assessment] (4,12,13)

Electrophysiologic Procedure Planning (4,7)

• Evaluation of pulmonary venous anatomy prior to radiofrequency ablation of atrial fibrillation and for follow-up when needed for evaluation of pulmonary vein stenosis (AUC 8)
• Non-invasive coronary vein mapping prior to placement of biventricular pacing leads (AUC 8)

Transcatheter Structural Intervention Planning 

• Evaluation for transcatheter aortic valve replacement (TAVR) (AUC 9) (8,14)
• When TTE and TEE cannot provide adequate imaging, CT imaging can be used for planning: robotic mitral valve repair, atrial septal defect closure, left atrial appendage closure, ventricular septal defect closure, endovascular grafts, and percutaneous pulmonic valve implantation (15)
• Evaluation for suitability of transcatheter mitral valve procedures, alone or in addition to TEE (16)

Aortic Pathology (3,8,11,17,18)

• CT, MR, or echo can be used for screening and follow-up, with CT and MR preferred for imaging beyond the proximal ascending thoracic aorta in the following scenarios:
  • Evaluation of dilated aortic sinuses or ascending aorta identified by TTE (AUC 8)
  • Suspected acute aortic pathology, such as dissection (AUC 9)
  • Re-evaluation of known aortic dilation or aortic dissection with a change in clinical status or cardiac examination or when findings would alter management (AUC 8)
  • Screening first-degree relatives of individuals with a history of thoracic aortic aneurysm or dissection, or an associated high-risk mutation for thoracic aneurysm in common (AUC 7)
  • Screening second-degree relative of a patient with thoracic aortic aneurysm, when the first-degree relative has aortic dilation, aneurysm, or dissection
  • Six-month follow-up after initial finding of a dilated thoracic aorta, for assessment of rate of change (AUC 8) 
  • Annual follow-up of enlarged thoracic aorta with size up to 4.4 cm
  • Biannual (twice/year) follow-up of enlarged aortic root ≥ 4.5 cm or showing growth rate ≥ 0.5 cm/year
• Patients with Marfan syndrome may undergo annual imaging with CT, MRI or TTE, with increase to biannual (twice-yearly) when diameter ≥ 4.5 cm or when expansions is > 0.5 cm/year (AUC 8)
• Patient with Turner syndrome should undergo initial imaging with CT, MRI, or TTE for evidence of dilatation of the ascending thoracic aorta. If imaging is normal and there are no risk factors for aortic dissection, repeat imaging should be performed every 5 -10 years, or if otherwise indicated. If the aorta is enlarged, appropriate follow-up imaging should be done according to size, as above
• Evaluation of the aorta in the setting of a known or suspected connective tissue disease or genetic condition that predisposes to aortic aneurysm or dissection (i.e., Loeys-Dietz, Ehlers-Danlos), with re-evaluation at 6 months for rate of expansion. 
• Complete evaluation with CMR from the cerebrovascular circulation to the pelvis is recommended with Loeys-Dietz syndrome.

ationale/Background

• Cardiac computed tomography (Heart CT) images the cardiac chambers, great vessels, valves, myocardium, and pericardium to assess cardiac structure and function, particularly when echocardiography (transthoracic echocardiography and transesophageal echocardiography) cannot provide adequate information
• CT imaging can be used for assessment of:
  • Structures of the heart (e.g., chambers, valves, great vessels, masses), as in this guideline
  • Quantitative level of calcium in the walls of the coronary arteries, in the separate coronary artery calcium (CAC) scoring guideline

Combination Studies
Chest MRA and Heart CT

• When medical necessity criteria indications are met for each Chest MRA (see CAM 743 for Chest MRA and Heart MRI (see CAM 719 for Heart MRI) or CT (such as for certain congenital malformations when evaluation of extra cardiac and cardiac structures are needed)

Abbreviations

References

1. Sachdeva R, Valente A M, Armstrong A K, Cook S C, Han B K et al. ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease: A Report of the American College of Cardiology Solution Set Oversight Committee and Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Pediatric Echocardiography. J Am Coll Cardiol. 2020; 75: 657-703. 10.1016/j.jacc.2019.10.002. 
2. Stout K, Daniels C, Aboulhosn J, Bozkurt B, Broberg C et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73: e81-e192. 10.1016/j.jacc.2018.08.1029. 
3. Doherty J U, Kort S, Mehran R, Schoenhagen P, Soman P et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2019; 73: 488-516. 10.1016/j.jacc.2018.10.038. 
4. Conte E, Mushtaq S, Muscogiuri G, Formenti A, Annoni A et al. The Potential Role of Cardiac CT in the Evaluation of Patients With Known or Suspected Cardiomyopathy: From Traditional Indications to Novel Clinical Applications. Front Cardiovasc Med. 2021; 8: 709124. 10.3389/fcvm.2021.709124. 
5. Ommen S, Mital S, Burke M, Day S, Deswal A et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020; 76: e159-e240. 10.1016/j.jacc.2020.08.045. 
6. Te Riele A, Tandri H, Sanborn D M, Bluemke D A. Noninvasive Multimodality Imaging in ARVD/C. JACC Cardiovasc Imaging. 2015; 8: 597-611. 10.1016/j.jcmg.2015.02.007. 
7. Taylor A J, Cerqueira M, Hodgson J M, Mark D, Min J et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2010; 56: 1864-94. 10.1016/j.jacc.2010.07.005. 
8. Doherty J U, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017; 70: 1647-1672. 10.1016/j.jacc.2017.07.732.
9. Otto C, Nishimura R, Bonow R, Carabello B, Erwin 3rd J et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021; 77: e25-e197. 10.1016/j.jacc.2020.11.018. 
10. Ascha M, Renapurkar R, Tonelli A. A review of imaging modalities in pulmonary hypertension. Ann Thorac Med. 2017; 12: 61-73. 10.4103/1817-1737.203742. 
11. Baumgartner H, Falk V, Bax J J, De Bonis M, Hamm C et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38: 2739-2791. 10.1093/eurheartj/ehx391. 
12. Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S et al. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2015; 16: 12-31. 10.1093/ehjci/jeu128. 
13. Klein A L, Abbara S, Agler D A, Appleton C P, Asher C R et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013; 26: 965-1012.e15. 10.1016/j.echo.2013.06.023. 
14. Otto C M, Kumbhani D J, Alexander K P, Calhoon J H, Desai M Y et al. 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults with Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017; 69: 1313-1346. 10.1016/j.jacc.2016.12.006. 
15. Pison L, Potpara T S, Chen J, Larsen T B, Bongiorni M G. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. Europace. 2015; 17: 642-6. 10.1093/europace/euv069. 
16. Wunderlich N C, Beigel R, Ho S Y, Nietlispach F, Cheng R et al. Imaging for Mitral Interventions: Methods and Efficacy. JACC Cardiovasc Imaging. 2018; 11: 872-901. 10.1016/j.jcmg.2018.02.024. 
17. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo R D et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2873-926. 10.1093/eurheartj/ehu281. 
18. Isselbacher E M, Preventza O, Black 3rd J, Augoustides J G, Beck A W et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 146: e334-e482. 10.1161/cir.0000000000001106. 

Coding Section

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive. 

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2024 Forward